Peter Libby, MD

Grants/Research Support: AstraZeneca, AtheroGenics, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Interleukin Genetics Inc., Kowa Research Institute, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, sanofi-aventis, Schering-Plough Corporation

Consultant/Advisory Board: AstraZeneca, AtheroGenics, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Interleukin Genetics Inc., Kowa Research Institute, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, sanofi-aventis, Schering-Plough Corporation

Speakers’ Bureau: AstraZeneca, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, sanofi-aventis

Dr Libby has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his presentation.